Subtype
Female Reproductive System Neoplasm
CI-CAN-00000885Explore in graph →
Non-malignant1,630 active trials11 approved drugs139 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000885Explore in graph →
Clinical trials
7,171 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04116320 | Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors(AM-003) | terminated | Phase 1 | 5 | Craig L Slingluff, JrOTHER | 1 | Jul 14, 2025 | clinicaltrials |
| NCT04577963 | A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 52 | HutchmedINDUSTRY | 1 | Jul 14, 2025 | clinicaltrials |
| NCT05274451 | A Study to Investigate LYL797 in Adults With Solid Tumors | terminated | Phase 1 | 57 | Lyell Immunopharma, Inc.INDUSTRY | 1 | Jul 1, 2025 | clinicaltrials |
| NCT04019288 | AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | terminated | Phase 1 / Phase 2 | 12 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT02419495 | Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies | terminated | Phase 1 | 221 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 4, 2025 | clinicaltrials |
| NCT03277482 | Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer | terminated | Phase 1 | 16 | Dana-Farber Cancer InstituteOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT03294694 | Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer | terminated | Phase 1 | 33 | Dana-Farber Cancer InstituteOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT04152018 | Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. | terminated | Phase 1 | 85 | PfizerINDUSTRY | 5 | May 28, 2025 | clinicaltrials |
| NCT04442126 | A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 52 | Numab Therapeutics AGINDUSTRY | 3 | May 23, 2025 | clinicaltrials |
| NCT05067972 | A Study of PF-07260437 in Advanced or Metastatic Solid Tumors(C4431001) | terminated | Phase 1 | 30 | PfizerINDUSTRY | 2 | May 6, 2025 | clinicaltrials |
| NCT04301011 | Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors(RAPTOR) | terminated | Phase 1 | 27 | Turnstone Biologics, Corp.INDUSTRY | 3 | Apr 23, 2025 | clinicaltrials |
| NCT04514692 | Bone Marrow Sparing Image-Guided Radiation Therapy (RT) Incorporating Novel Use of GCSF and FDG-PET Imaging | terminated | Phase 1 / Phase 2 | 7 | Stanford UniversityOTHER | 1 | Apr 23, 2025 | clinicaltrials |
| NCT04875806 | A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 40 | NextCure, Inc.INDUSTRY | 1 | Apr 22, 2025 | clinicaltrials |
| NCT03829501 | A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies | terminated | Phase 1 / Phase 2 | 222 | Kymab LimitedINDUSTRY | 6 | Apr 2, 2025 | clinicaltrials |
| NCT03585764 | MOv19-BBz CAR T Cells in aFR Expressing Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | terminated | Phase 1 | 46 | University of PennsylvaniaOTHER | 1 | Mar 26, 2025 | clinicaltrials |
| NCT06257758 | A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors | terminated | Phase 1 / Phase 2 | 6 | Valerio TherapeuticsINDUSTRY | 1 | Mar 17, 2025 | clinicaltrials |
| NCT04254107 | A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer | terminated | Phase 1 | 133 | Seagen Inc.INDUSTRY | 6 | Feb 10, 2025 | clinicaltrials |
| NCT05229900 | A Study of SGN-ALPV in Advanced Solid Tumors | terminated | Phase 1 | 43 | Seagen Inc.INDUSTRY | 5 | Feb 10, 2025 | clinicaltrials |
| NCT04665921 | A Study of SGN-STNV in Advanced Solid Tumors | terminated | Phase 1 | 111 | Seagen Inc.INDUSTRY | 6 | Feb 7, 2025 | clinicaltrials |
| NCT05500508 | Oral AMXT 1501 Dicaprate in Combination With IV DFMO | terminated | Phase 1 / Phase 2 | 15 | Aminex Therapeutics, Inc.INDUSTRY | 2 | Dec 24, 2024 | clinicaltrials |
| NCT03549000 | A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies. | terminated | Phase 1 | 127 | Novartis PharmaceuticalsINDUSTRY | 7 | Dec 13, 2024 | clinicaltrials |
| NCT04939701 | Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants | terminated | Phase 1 / Phase 2 | 16 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Dec 11, 2024 | clinicaltrials |
| NCT04826198 | Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 Months(REVOCAN) | terminated | Phase 1 / Phase 2 | 13 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Dec 5, 2024 | clinicaltrials |
| NCT05261490 | Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer | terminated | Phase 1 / Phase 2 | 10 | PfizerINDUSTRY | 1 | Nov 19, 2024 | clinicaltrials |
| NCT04493619 | PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer | terminated | Phase 1 / Phase 2 | 37 | Opna Bio LLCINDUSTRY | 2 | Nov 4, 2024 | clinicaltrials |
| NCT06034860 | Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types | terminated | Phase 1 | 15 | Molecular Templates, Inc.INDUSTRY | 1 | Nov 1, 2024 | clinicaltrials |
| NCT03691376 | Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | terminated | Phase 1 | 4 | Roswell Park Cancer InstituteOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03644342 | Study of Niraparib With Radiotherapy for Treatment of Metastatic Invasive Carcinoma of the Cervix(NIVIX) | terminated | Phase 1 / Phase 2 | 4 | Michelle S LudwigOTHER | 1 | Sep 3, 2024 | clinicaltrials |
| NCT00819169 | QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors | terminated | Phase 1 / Phase 2 | 89 | NantCell, Inc.INDUSTRY | 0 | Aug 20, 2024 | clinicaltrials |
| NCT06065059 | Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors | terminated | Phase 1 / Phase 2 | 7 | Tango Therapeutics, Inc.INDUSTRY | 1 | Aug 13, 2024 | clinicaltrials |
| NCT05001282 | A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα) | terminated | Phase 1 / Phase 2 | 79 | Elucida OncologyINDUSTRY | 1 | Aug 7, 2024 | clinicaltrials |
| NCT03127098 | QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer | terminated | Phase 1 / Phase 2 | 3 | NantCell, Inc.INDUSTRY | 1 | Aug 6, 2024 | clinicaltrials |
| NCT03323398 | Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies | terminated | Phase 1 / Phase 2 | 79 | ModernaTX, Inc.INDUSTRY | 1 | Jul 31, 2024 | clinicaltrials |
| NCT04628780 | Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors | terminated | Phase 1 | 37 | PfizerINDUSTRY | 1 | Jul 29, 2024 | clinicaltrials |
| NCT04408599 | A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 46 | NextCure, Inc.INDUSTRY | 1 | Jul 25, 2024 | clinicaltrials |
| NCT05769959 | Study of RO7515629 in Participants With HLA-G Positive Solid Tumors | terminated | Phase 1 | 3 | Hoffmann-La RocheINDUSTRY | 1 | Jul 9, 2024 | clinicaltrials |
| NCT03621982 | Study of ADCT-301 in Patients With Selected Advanced Solid Tumors | terminated | Phase 1 | 78 | ADC Therapeutics S.A.INDUSTRY | 3 | Jun 13, 2024 | clinicaltrials |
| NCT04726332 | Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101) | terminated | Phase 1 | 52 | ExelixisINDUSTRY | 1 | May 14, 2024 | clinicaltrials |
| NCT05107739 | A Study of DeTIL-0255 in Adults With Advanced Malignancies | terminated | Phase 1 | 5 | Nurix Therapeutics, Inc.INDUSTRY | 1 | May 3, 2024 | clinicaltrials |
| NCT01279291 | Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer | terminated | Phase 1 | 22 | Kyowa Kirin Co., Ltd.INDUSTRY | 1 | Apr 26, 2024 | clinicaltrials |
| NCT05538624 | A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary | terminated | Phase 1 / Phase 2 | 14 | Avenge Bio, IncINDUSTRY | 1 | Apr 24, 2024 | clinicaltrials |
| NCT03311334 | A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 47 | Sumitomo Pharma America, Inc.INDUSTRY | 2 | Apr 18, 2024 | clinicaltrials |
| NCT05061537 | Study of PF-07263689 in Participants With Selected Advanced Solid Tumors | terminated | Phase 1 | 13 | PfizerINDUSTRY | 1 | Apr 12, 2024 | clinicaltrials |
| NCT00889733 | Intraperitoneal (IP) Cisplatin Given With Paclitaxel to Treat Epithelial Ovarian Cancer(OVHM-01) | terminated | Phase 1 / Phase 2 | 9 | University Health Network, TorontoOTHER | 1 | Mar 26, 2024 | clinicaltrials |
| NCT01962948 | Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | terminated | Phase 1 / Phase 2 | 12 | Fox Chase Cancer CenterOTHER | 1 | Mar 26, 2024 | clinicaltrials |
| NCT04682431 | A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | terminated | Phase 1 | 127 | Ikena OncologyINDUSTRY | 1 | Mar 22, 2024 | clinicaltrials |
| NCT04691375 | A Study of PY314 in Subjects With Advanced Solid Tumors | terminated | Phase 1 | 86 | Ikena OncologyINDUSTRY | 1 | Mar 22, 2024 | clinicaltrials |
| NCT04586335 | Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. | terminated | Phase 1 | 24 | Haihe Biopharma Co., Ltd.INDUSTRY | 3 | Mar 21, 2024 | clinicaltrials |
| NCT04396340 | First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2b | terminated | Phase 1 | 31 | Mersana TherapeuticsINDUSTRY | 1 | Mar 15, 2024 | clinicaltrials |
| NCT05215496 | [18F]Fluoro-PEG-folate PET/CT Imaging in Epithelial Ovarian Cancer | terminated | Phase 1 | 5 | Lioe-Fee de Geus-Oei, MD PhDOTHER | 1 | Mar 15, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Jul 14, 2025source: clinicaltrials